Long‐COVID symptoms improved after MDMA and psilocybin therapy: A case report
Clinical Case Reports – May 28, 2024
Source: OpenAlex
Summary
A 41-year-old fully vaccinated woman with debilitating Long-COVID post-Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection found remarkable relief. She self-medicated with psilocybin, a potent hallucinogen, and MDMA. This compelling case suggests these psychedelics, explored in Complementary and Alternative Medicine Studies, offer new avenues for medicine. Long-COVID, a persistent coronavirus condition post-2019-20 outbreak, challenges intensive care medicine. Rigorous drug studies, including biochemical analysis, are essential to understand their therapeutic potential.
Abstract
Key Clinical Message Long‐COVID syndrome lacks effective holistic treatment options. We present a case of a 41‐year‐old fully vaccinated female with Long‐COVID syndrome who obtained significant symptomatic relief after self‐medicating with psilocybin and MDMA. Abstract Long‐COVID, a syndrome persisting after the acute phase of coronavirus disease 2019 (COVID‐19), lacks effective holistic treatment options. We present a case of a 41‐year‐old fully vaccinated female with Long‐COVID syndrome who obtained significant symptomatic relief by self‐prescribing psilocybin and MDMA. Future research is needed to assess safety and efficacy.